China’s Pegbio Co. Ltd. is planning a Hong Kong IPO to advance PB-119, its main glucagon-like peptide 1 receptor agonist for diabetes nearing domestic approval, as it hopes to transition to an operating profit.

Biopharmas raising money in public or private financings, including: Apogee, Aslan, Cybin.

Med-tech firms raising money in public or private financings, including: Zephyr AI.

With early phase II trial data from Cognition Therapeutics Inc.’s lead candidate, CT-1812, for Alzheimer’s disease expected in mid-2024, the firm is hoping to raise $11.5 million from an underwritten public offering of about 6.6 million shares, priced at $1.75 each.

With a second batch of phase Ib data from the trial testing RGLS-8429 in hand from Regulus Therapeutics Inc., Wall Street is looking forward to results from the third cohort in midyear and weighing prospects with the compound in autosomal dominant polycystic kidney disease. Screening of the fourth cohort will start during the second quarter. Meanwhile, the company has begun to mull a pivotal phase II trial that would launch in the middle of next year, and may help with accelerated approval by the U.S. FDA.

Foreign investment in China’s biopharma sector is beginning to pick up after the hit of severe pandemic restrictions, and as Western governments look to revive trading relationships following a spate of diplomatic rows.

Biopharmas raising money in public or private financings, including: Eupraxia, Lirum, Recce, Siolta.

Med-tech firms raising money in public or private financings, including: Irthythm, Sooma, Tierra Biosciences.

Biopharmas in Asia-Pacific raising money in public or private financings: Jhong Biotech, Nyrada, Recce.